PF-03550096 is a synthetic cannabinoid (CB) that selectively targets the peripheral CB2 receptor over the central CB1 receptor (Kis = 7.9 and 1,500 nM for human isoforms, respectively).
CAS：910376-39-5
分子式：C19H28N4O4
分子量：376.5
纯度：98%
存储：Store at -20°C

Background:

PF-03550096 is a synthetic cannabinoid (CB) that selectively targets the peripheral CB2 receptor over the central CB1 receptor (Kis = 7.9 and 1,500 nM for human isoforms, respectively).[1] [2] It shows similar selectivity for inhibiting forskolin-stimulated cAMP production in CHO cells expressing human CB1 and CB2 receptors (EC50s = 450 and 2.1 nM, respectively).[2] PF-03550096 is orally bioavailable and significantly reduces colonic pain induced by 2,4,6-trinitrobenzene sulfonic acid in rats.[2] This product is intended for forensic and research applications.

Reference:
[1]. Ando, K., Buchler, I., Hedge, S.G., et al. Benzimidazolone derivatives. PCT/IB2007/002583, (2009).
[2]. Kikuchi, A., Ohashi, K., Sugie, Y., et al. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. Journal of Pharmacological Sciences 106(2), 219-224 (2008).